


Pharmaceuticals & Biotechnology | Small Cap
Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
40.50
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
29.16
P/B RATIO
4.03
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
4.13
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
16.84
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹268.9 as on Aug 6, 2026.
The company exhibits excellent growth, driven by strong revenue, operating profit, EPS, asset, and net income growth rates. This indicates the company is expanding its operations and profitability effectively. The company's prospects are very encouraging, reflecting its ability to capitalize on market opportunities and increase shareholder value. The company may be able to achieve higher growth rate in future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.36 | 24.21 | 17.55 | 20.49 | 12.5 |
| Operating Profit Growth Rate | -23.82 | 31.27 | 35 | 15.25 | 13.61 |
| Earnings Per Share (EPS) Growth | -21.7 | 30.38 | 17.69 | 21.39 | 9.76 |
| Asset Growth Rate | 33.22 | 33.86 | 22.42 | 20.85 | 19.17 |
| Net Income Growth Rate | -21.76 | 41.71 | 18.87 | 21.59 | 9.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 9 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 10 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤14th Nov 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT